Klaus Scholich Selected Research

Zymosan

1/2021	Lipidomic analysis of local inflammation models shows a specific systemic acute phase response to lipopolysaccharides.
1/2020	Bacterial and Fungal Toll-Like Receptor Activation Elicits Type I IFN Responses in Mast Cells.
1/2018	The G2A Receptor Controls Polarization of Macrophage by Determining Their Localization Within the Inflamed Tissue.
1/2018	The oxidized linoleic acid metabolite 12,13-DiHOME mediates thermal hyperalgesia during inflammatory pain.
1/2018	Myc binding protein 2 suppresses M2-like phenotypes in macrophages during zymosan-induced inflammation in mice.
1/2017	The leukotriene B4 receptors BLT1 and BLT2 form an antagonistic sensitizing system in peripheral sensory neurons.
1/2017	GPVI and Thromboxane Receptor on Platelets Promote Proinflammatory Macrophage Phenotypes during Cutaneous Inflammation.
7/2014	Neutrophils mediate edema formation but not mechanical allodynia during zymosan-induced inflammation.
2/2014	Prostacyclin regulates spinal nociceptive processing through cyclic adenosine monophosphate-induced translocation of glutamate receptors.
11/2012	Overdose of the histamine H₃ inverse agonist pitolisant increases thermal pain thresholds.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Klaus Scholich Research Topics

Disease

22	Pain (Aches) 01/2021 - 04/2003
20	Inflammation (Inflammations) 01/2021 - 07/2006
16	Hyperalgesia 01/2018 - 09/2005
11	Neuralgia (Stump Neuralgia) 12/2020 - 06/2008
7	Hypersensitivity (Allergy) 01/2022 - 05/2012
7	Neoplasms (Cancer) 01/2019 - 04/2003
4	Edema (Dropsy) 01/2021 - 07/2014
3	Colitis 02/2022 - 01/2017
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2022 - 01/2019
2	Colitis-Associated Neoplasms 02/2022 - 01/2019
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 01/2017
2	Atherosclerosis 10/2019 - 05/2011
2	Fever (Fevers) 01/2018 - 07/2006
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2014 - 06/2012
1	Painful Neuropathy 01/2022
1	Ischemic Stroke 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Vascular Diseases (Vascular Disease) 01/2022
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022
1	Acute-Phase Reaction 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 12/2020
1	Acute Pain 12/2020
1	Neurogenic Inflammation 01/2019
1	Carcinogenesis 01/2019

Drug/Important Bio-Agent (IBA)

15	ZymosanIBA 01/2021 - 09/2005
10	LipidsIBA 01/2021 - 01/2013
7	ProstaglandinsIBA 01/2018 - 04/2008
5	LigandsIBA 01/2022 - 01/2018
5	Dinoprostone (PGE2)FDA Link 01/2018 - 09/2005
4	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 01/2017
4	Pharmaceutical PreparationsIBA 12/2020 - 08/2006
4	Ion Channels (Ion Channel)IBA 12/2020 - 02/2011
4	Cytostatic AgentsIBA 12/2020 - 12/2014
4	Sphingosine-1-Phosphate ReceptorsIBA 01/2019 - 06/2015
4	Proteins (Proteins, Gene)FDA Link 06/2012 - 09/2005
4	Formaldehyde (Formol)FDA Link 09/2011 - 09/2005
3	SphingolipidsIBA 02/2022 - 10/2012
3	CytokinesIBA 12/2020 - 01/2017
3	Fingolimod Hydrochloride (FTY720)FDA Link 03/2016 - 06/2008
3	CalciumIBA 11/2012 - 09/2011
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2022
2	EpitopesIBA 01/2022 - 01/2018
2	Insulin (Novolin)FDA Link 01/2022 - 01/2017
2	LipopolysaccharidesIBA 01/2021 - 01/2011
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2020 - 01/2017
2	ChemokinesIBA 12/2020 - 05/2011
2	EicosanoidsIBA 01/2020 - 01/2018
2	G2A receptorIBA 01/2020 - 01/2017
2	ThromboxanesIBA 01/2019 - 01/2017
2	Epoxide HydrolasesIBA 01/2018 - 10/2011
2	Freund's AdjuvantIBA 01/2018 - 11/2017
2	dihydroceramide desaturaseIBA 01/2017 - 06/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 11/2016 - 06/2015
2	Protein Isoforms (Isoforms)IBA 11/2016 - 04/2009
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 03/2016 - 02/2009
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 10/2015 - 01/2005
2	Analgesics (Analgesic Drugs)IBA 12/2014 - 01/2013
2	Cyclooxygenase InhibitorsIBA 03/2014 - 01/2013
2	Epoprostenol (Prostacyclin)FDA LinkGeneric 03/2014 - 02/2014
2	Prostaglandins EIBA 01/2011 - 04/2008
2	Opioid Analgesics (Opioids)IBA 03/2009 - 04/2003
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2008 - 07/2006
1	Dextrans (Dextran)FDA Link 02/2022
1	SodiumIBA 02/2022
1	AzoxymethaneIBA 02/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	GW9508IBA 01/2022
1	Axitinib (AG 013736)IBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	Streptozocin (Streptozotocin)FDA Link 01/2022
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022
1	We 201IBA 01/2021
1	PlatinumIBA 12/2020
1	LysophospholipidsIBA 12/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2020
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 12/2020
1	Immunoglobulin E (IgE)IBA 01/2020
1	9-hydroxy-10,12-octadecadienoic acidIBA 01/2020
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020
1	CXC ChemokinesIBA 10/2019
1	AMP-Activated Protein KinasesIBA 07/2019
1	AICA ribonucleotide (ZMP)IBA 07/2019
1	LyasesIBA 01/2019
1	Interleukin-12 (IL 12)IBA 01/2019
1	CalcineurinIBA 01/2019
1	7- (3- (3- hydroxy- 4- (4'- iodophenoxy)- 1- butenyl)- 7- oxabicyclo(2.2.1)heptan- 2- yl)- 5- heptenoic acidIBA 01/2019
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2019
1	sphingosine kinaseIBA 01/2019
1	Interleukin-23 (Interleukin 23)IBA 01/2019
1	Capsaicin (Zostrix)FDA Link 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Thromboxane Receptors (Thromboxane Receptor)IBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 01/2019
1	CytochromesIBA 01/2018
1	Linoleic Acid (Linoleate)IBA 01/2018
1	CC ChemokinesIBA 01/2018
1	IronIBA 01/2018

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2017 - 12/2014
3	Therapeutics 11/2016 - 08/2006
1	Pain Management 01/2018